Company profile: Chroma Medicine
1.1 - Company Overview
Company description
- Provider of genetic medicines built on an epigenetic editing platform that uses programmable editors to silence, activate, or regulate multiple genes by controlling chromatin conformation; single-dose genomic medicines for precise, predictable, durable treatment; multiplex epigenetic editing to enhance allogeneic CAR T cells; and a PCSK9-targeted editor to lower cholesterol and LDL-C.
Products and services
- Epigenetic Editing Platform: A modular platform leveraging programmable epigenetic editors to control chromatin conformation and silence, activate, or regulate multiple genes simultaneously for medicine development
- Multiplex Epigenetic Editing: A multiplex technology that simultaneously edits multiple genes to enhance functionality in therapies such as allogeneic CAR T cells by enabling coordinated gene regulation
- Single-dose Genomic Medicines: Epigenetics-based therapeutics that deliver precise, predictable, and durable treatments for various diseases with a single administration through targeted gene regulation
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Chroma Medicine
BioIVT
HQ: United States
Website
- Description: Provider of biological and in vitro products and services for biopharmaceutical, diagnostic, and biotechnology organizations. Offerings include in vivo ADME/PK studies, bioanalytical services, biospecimen characterization, consulting for drug R&D, long-term hepatocyte culture systems (HEPATOPAC and HEPATOMUNE), and Human AB Serum for cell culture.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioIVT company profile →
SeQure Dx
HQ: United States
Website
- Description: Provider of safety data and diagnostic platforms for on- and off-target CRISPR gene editing therapies. Offers NoteSeQ (ONE-seq) for profiling off-target sites, ScopeSeQ for validating candidate edits via next-generation sequencing, risk assessment across the development lifecycle, discovery/IND support, clinical trial patient risk management, and post-approval diagnostic management with patient and physician education.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SeQure Dx company profile →
Automated Lab Solutions
HQ: Germany
Website
- Description: Provider of life science robotics and automation, including the CellCelector automated system for fluorescence imaging, selection, and image-based sorting/picking of single cells, clusters, adherent cell colonies, and clones from semi-solid media; rare single cell isolation; single cell cloning; stem cell picking; the Incubator FlowBox laminar flow cabinet; and automation components.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Automated Lab Solutions company profile →
Floragenex
HQ: United States
Website
- Description: Provider of innovative genomic analysis solutions for human, plant, and animal systems. Oregon-based privately owned biotechnology company delivering results in hundreds of genomics studies since 2007, supporting research in genetics, ecology, evolutionary biology, and biomedical fields.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Floragenex company profile →
enGene
HQ: Canada
Website
- Description: Provider of biotechnological treatments for mucosal diseases by inducing therapeutic proteins.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full enGene company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Chroma Medicine
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Chroma Medicine
2.2 - Growth funds investing in similar companies to Chroma Medicine
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Chroma Medicine
4.2 - Public trading comparable groups for Chroma Medicine
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →